Developer docs
API playgroundTry for free, no card

Search company profiles

PerturbAI

Full company profile

uuid00swo5z

Namestring
PerturbAI
Legal namestring
PerturbAI
Websiteurl
perturb.ai
Company typeenum
Private
Founded yearint
2025
Descriptiontext

PerturbAI is an AI-native therapeutics company founded in 2025 and headquartered in San Francisco that combines scalable in vivo CRISPR perturbation (Perturb-seq) with proprietary AI models to accelerate drug discovery. Its core platform, the PerturbAI Engine, generates organism-scale perturbation atlases that link genes to cells, circuits, and disease, with the flagship being the world's largest brain-wide in vivo CRISPR atlas — 8 million cells spanning hundreds of neuronal cell types, generated in collaboration with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics. The company is developing therapeutics for complex metabolic and chronic diseases including neurodegeneration, psychiatric, metabolic, and rare disease indications.

The platform is anchored by a proprietary AI Stack comprising autonomous agents (biological, clinical, and grader agents), reasoning models, and predictive models trained on causal in vivo biology data, integrated with NVIDIA BioNeMo Agent Toolkit, RAPIDS-singlecell, and (for public-facing tools) OpenAI workflows. PerturbAI's go-to-market combines enterprise partnership and licensing for therapeutic development with a product-led growth motion through public release of the atlas on Hugging Face and via NVIDIA AI Blueprint for Single-Cell Analysis, with 30,000+ downloads since March 2026. The company emerged from stealth on March 17, 2026, is pre-revenue, and operates with 1–10 employees led by co-founder and CEO Grace Zheng, Ph.D., co-founder Xin Jin, and COO Caroline Moon. Strategic partners include NVIDIA (core), Allen Institute for Brain Science (core), 10x Genomics (core), and OpenAI (public tools); the company closed an oversubscribed pre-seed round in Q3 2025.

Short descriptiontext

PerturbAI is an AI-native therapeutics company combining scalable in vivo CRISPR perturbation with causal AI models to generate organism-scale perturbation atlases for drug discovery, serving pharmaceutical and biotechnology companies developing treatments for complex metabolic and chronic diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, in vivo CRISPR, single-cell genomics, target identification, functional genomics
Industry5 codes
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development and Licensing
TypeSubscription Recurring
Description

PerturbAI develops therapeutics for complex metabolic and chronic diseases using its in vivo CRISPR platform and causal AI models. Revenue would be generated through drug development partnerships, licensing deals, and eventual product commercialization.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

PerturbAI operates an AI-native drug discovery platform that combines in vivo CRISPR Perturb-seq functional genomics screens with proprietary AI models to map gene-phenotype relationships at single-cell resolution. The core deliverable is a target identification and validation engine, supported by reference datasets such as the Whole-Brain CRISPR Atlas (approximately 8 million cells) that serve as training data for the company's predictive models. The platform is offered to pharmaceutical and biotechnology partners and academic researchers seeking novel, in vivo-validated therapeutic targets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Atlas downloaded over 30,000 times within months of release
+2 more records
Product overview1 text field

PerturbAI is an AI-native therapeutics company offering a unified platform that combines scalable in vivo CRISPR perturbation with proprietary AI to accelerate drug discovery. The core offering consists of the PerturbAI Engine, which generates organism-scale perturbation atlases, powered by the company's Whole-Brain CRISPR Atlas (8 million cells) and supported by a proprietary AI stack of autonomous agents, reasoning models, and predictive models. Public analysis tools enable the broader research community to explore the atlas via NVIDIA and Hugging Face integrations. The platform enables a closed-loop workflow from causal data generation in living systems to biological insight, target prioritization, and therapeutic hypothesis development in days/weeks rather than months/years.

Product and service3 records
1PerturbAI Engine
CategoryAI Drug Discovery Platform
Description

AI-native therapeutics platform that combines in vivo CRISPR Perturb-seq screens with proprietary AI models to map gene-phenotype relationships at single-cell resolution and identify novel therapeutic targets for pharmaceutical and biotechnology partners.

2Whole-Brain CRISPR Atlas
CategoryFunctional Genomics Dataset
Description

Reference single-cell dataset of approximately 8 million brain cells produced through in vivo CRISPR Perturb-seq, serving as a training corpus for the PerturbAI Engine and as a public resource enabling researchers to study gene function and disease mechanisms.

3Proprietary AI Stack
CategoryAI Foundation Models for Drug Discovery
Description

Proprietary machine learning foundation models trained on PerturbAI's in vivo single-cell perturbation datasets to predict gene-phenotype relationships and prioritize therapeutic targets for partners.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Collaboration with OpenAI to develop public tools and workflows allowing researchers to explore, analyze, and reason over the whole-brain CRISPR atlas dataset.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-23
Description

PerturbAI became a new member of NVIDIA Inception startup program, through which they will continue working with NVIDIA to help make scalable analysis environments more accessible to the research community.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-17
Description

Collaboration with NVIDIA to generate and analyze the world's largest in vivo CRISPR atlas. NVIDIA provides computational infrastructure including BioNeMo platform, AI Blueprint for Single-Cell Analysis, and RAPIDS-singlecell tools for near-real-time processing of the 8 million-cell dataset. Partnership enables AI agents to call high-performance domain-specific tools.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Collaboration integrating PerturbAI's functional perturbation data with the Allen Institute's high-resolution cell-type taxonomy. Hongkui Zeng, EVP and senior author of the Allen Brain Cell Atlas, contributed to precisely mapping each gene's perturbation effects onto known neuronal circuits.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-17
Description

Collaboration with 10x Genomics to generate and analyze the CRISPR atlas using large-scale CRISPR screening and single-nucleus RNA sequencing technologies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PerturbAI

AI Drug Discovery Platformperturb.ai

PerturbAI is an AI-native therapeutics company combining scalable in vivo CRISPR perturbation with causal AI models to generate organism-scale perturbation atlases for drug discovery, serving pharmaceutical and biotechnology companies developing treatments for complex metabolic and chronic diseases.

What PerturbAI does

PerturbAI is an AI-native therapeutics company founded in 2025 and headquartered in San Francisco that combines scalable in vivo CRISPR perturbation (Perturb-seq) with proprietary AI models to accelerate drug discovery. Its core platform, the PerturbAI Engine, generates organism-scale perturbation atlases that link genes to cells, circuits, and disease, with the flagship being the world's largest brain-wide in vivo CRISPR atlas — 8 million cells spanning hundreds of neuronal cell types, generated in collaboration with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics. The company is developing therapeutics for complex metabolic and chronic diseases including neurodegeneration, psychiatric, metabolic, and rare disease indications.

The platform is anchored by a proprietary AI Stack comprising autonomous agents (biological, clinical, and grader agents), reasoning models, and predictive models trained on causal in vivo biology data, integrated with NVIDIA BioNeMo Agent Toolkit, RAPIDS-singlecell, and (for public-facing tools) OpenAI workflows. PerturbAI's go-to-market combines enterprise partnership and licensing for therapeutic development with a product-led growth motion through public release of the atlas on Hugging Face and via NVIDIA AI Blueprint for Single-Cell Analysis, with 30,000+ downloads since March 2026. The company emerged from stealth on March 17, 2026, is pre-revenue, and operates with 1–10 employees led by co-founder and CEO Grace Zheng, Ph.D., co-founder Xin Jin, and COO Caroline Moon. Strategic partners include NVIDIA (core), Allen Institute for Brain Science (core), 10x Genomics (core), and OpenAI (public tools); the company closed an oversubscribed pre-seed round in Q3 2025.

PerturbAI firmographics

Firmographics
Name
PerturbAI
Legal name
PerturbAI
Website
https://perturb.ai
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
PerturbAI is an AI-native therapeutics company combining scalable in vivo CRISPR perturbation with causal AI models to generate organism-scale perturbation atlases for drug discovery, serving pharmaceutical and biotechnology companies developing treatments for complex metabolic and chronic diseases.
Ownership category
akta.pro rank

PerturbAI industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • In vivo CRISPR
  • Single-cell genomics
  • Target identification
  • Functional genomics

Where PerturbAI is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PerturbAI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Therapeutic Development and Licensing: PerturbAI develops therapeutics for complex metabolic and chronic diseases using its in vivo CRISPR platform and causal AI models. Revenue would be generated through drug development partnerships, licensing deals, and eventual product commercialization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

PerturbAI product offering

Product offering

Core offering

PerturbAI operates an AI-native drug discovery platform that combines in vivo CRISPR Perturb-seq functional genomics screens with proprietary AI models to map gene-phenotype relationships at single-cell resolution. The core deliverable is a target identification and validation engine, supported by reference datasets such as the Whole-Brain CRISPR Atlas (approximately 8 million cells) that serve as training data for the company's predictive models. The platform is offered to pharmaceutical and biotechnology partners and academic researchers seeking novel, in vivo-validated therapeutic targets.

Product overview

PerturbAI is an AI-native therapeutics company offering a unified platform that combines scalable in vivo CRISPR perturbation with proprietary AI to accelerate drug discovery. The core offering consists of the PerturbAI Engine, which generates organism-scale perturbation atlases, powered by the company's Whole-Brain CRISPR Atlas (8 million cells) and supported by a proprietary AI stack of autonomous agents, reasoning models, and predictive models. Public analysis tools enable the broader research community to explore the atlas via NVIDIA and Hugging Face integrations. The platform enables a closed-loop workflow from causal data generation in living systems to biological insight, target prioritization, and therapeutic hypothesis development in days/weeks rather than months/years.

Differentiator

Problem solved

Functional benefit

Products and services

  • PerturbAI Engine AI-native therapeutics platform that combines in vivo CRISPR Perturb-seq screens with proprietary AI models to map gene-phenotype relationships at single-cell resolution and identify novel therapeutic targets for pharmaceutical and biotechnology partners.
  • Whole-Brain CRISPR Atlas Reference single-cell dataset of approximately 8 million brain cells produced through in vivo CRISPR Perturb-seq, serving as a training corpus for the PerturbAI Engine and as a public resource enabling researchers to study gene function and disease mechanisms.
  • Proprietary AI Stack Proprietary machine learning foundation models trained on PerturbAI's in vivo single-cell perturbation datasets to predict gene-phenotype relationships and prioritize therapeutic targets for partners.

Quantifiable outcome

  • Atlas downloaded over 30,000 times within months of release
  • +2 more outcomes

Companies that use PerturbAI

Customer profile

Segments2 records

Ideal customer profiles2 records

PerturbAI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature4 records

PerturbAI partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • OpenAIminorStrategic or Co-development Partner · 23 June 2026Collaboration with OpenAI to develop public tools and workflows allowing researchers to explore, analyze, and reason over the whole-brain CRISPR atlas dataset.
  • NVIDIA InceptionminorGTM or Marketing Partner · 23 June 2026PerturbAI became a new member of NVIDIA Inception startup program, through which they will continue working with NVIDIA to help make scalable analysis environments more accessible to the research community.
  • NVIDIAcoreTechnology or Integration · 17 March 2026Collaboration with NVIDIA to generate and analyze the world's largest in vivo CRISPR atlas. NVIDIA provides computational infrastructure including BioNeMo platform, AI Blueprint for Single-Cell Analysis, and RAPIDS-singlecell tools for near-real-time processing of the 8 million-cell dataset. Partnership enables AI agents to call high-performance domain-specific tools.
  • Allen Institute for Brain SciencecoreStrategic or Co-development Partner · 17 March 2026Collaboration integrating PerturbAI's functional perturbation data with the Allen Institute's high-resolution cell-type taxonomy. Hongkui Zeng, EVP and senior author of the Allen Brain Cell Atlas, contributed to precisely mapping each gene's perturbation effects onto known neuronal circuits.
  • 10x GenomicscoreTechnology or Integration · 17 March 2026Collaboration with 10x Genomics to generate and analyze the CRISPR atlas using large-scale CRISPR screening and single-nucleus RNA sequencing technologies.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

PerturbAI competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

PerturbAI social profiles

Digital presence

PerturbAI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PerturbAI leadership team

Management profile

Number of profiles

Profiles3 records

PerturbAI funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PerturbAI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PerturbAI

What does PerturbAI do?

PerturbAI operates an AI-native drug discovery platform that combines in vivo CRISPR Perturb-seq functional genomics screens with proprietary AI models to map gene-phenotype relationships at single-cell resolution. The core deliverable is a target identification and validation engine, supported by reference datasets such as the Whole-Brain CRISPR Atlas (approximately 8 million cells) that serve as training data for the company's predictive models. The platform is offered to pharmaceutical and biotechnology partners and academic researchers seeking novel, in vivo-validated therapeutic targets.

Is PerturbAI a public or private company?

PerturbAI is a private company. It is classified as venture growth investor backed and is currently operating.

When was PerturbAI founded?

PerturbAI was founded in 2025. It employs 1 to 10 people.

Where is PerturbAI based?

PerturbAI is headquartered in San Francisco, United States, in the North America region.

How does PerturbAI make money?

One revenue line is on record: therapeutic Development and Licensing.

Does PerturbAI have an API?

No public API is recorded for PerturbAI.

What industry is PerturbAI in?

PerturbAI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournPerturbAI and OpenAI Unveil First-of-Its-Kind AI Reasoning Agents to Scale Biomedical DiscoveryPerturbAI and OpenAI unveiled AI reasoning agents to interpret biomedical data, developed with Scripps Research. Human experts preferred the agents' interpretations 75% of the time, and the system analyzed a whole-brain atlas in 32 minutes. The partnership aims to make drug-target discovery more systematic.GenengnewsPerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical DiscoveryPerturbAI and OpenAI released a year-long AI reasoning framework for biomedical discovery, analyzing PerturbAI's whole-brain atlas with thousands of parallel agents. The system recovered conclusions and predicted effects in 32 minutes, and human experts preferred its interpretations 75% of the time. The partnership now expands to joint drug-target discovery using PerturbAI's causal in vivo data.The Pharma LetterPerturbAI and OpenAI use AI agents to hunt for drug targetsPerturbAI and OpenAI announced results from a collaboration using nearly 2,000 AI agents to interpret biological data, generating hypotheses for drug-target discovery. Working with Scripps Research, they analyzed data from millions of mouse brain cells in 32 minutes. The findings come from a year-long collaboration aimed at connecting experimental results with published research.PR NewswirePerturbAI and OpenAI Unveil First-of-Its-Kind AI Reasoning Agents to Scale Biomedical DiscoveryPerturbAI and OpenAI unveiled AI reasoning agents that analyzed a whole-brain genomic atlas in 32 minutes, surfacing leads for further investigation. Human experts preferred the agents' interpretations 75% of the time in blinded comparisons. The partnership now applies the framework to joint drug-target discovery.OpenAIUsing thousands of AI agents to uncover new leads in biological dataOpenAI, PerturbAI, and Scripps Research used thousands of AI agents to analyze data from millions of mouse brain cells in 32 minutes, uncovering unexpected biological connections. The agents cited over 700 references, while a single agent cited only 11, and human experts preferred the distributed-agent reports 75% of the time.The Pharma LetterPerturbAI emerges with large-scale in vivo CRISPR atlasPerturbAI emerged from stealth with a large-scale in vivo CRISPR atlas spanning 8 million brain-wide cells. The dataset aims to map gene function directly in living tissue, marking an early shift toward organism-level data in drug discovery.Stock TitanPerturbAI unveils 8M-cell in vivo CRISPR atlasPerturbAI emerged from stealth on March 17, 2026, releasing the world's largest in vivo CRISPR atlas containing 8 million brain-wide cells, generated in collaboration with NVIDIA, the Allen Institute for Brain Science, and 10x Genomics. The dataset represents the largest known causal genomics resource generated in living tissue and establishes a new category of biological data enabling systems-level understanding of disease. The company is utilizing this in vivo CRISPR platform and causal AI models to develop therapeutics for complex metabolic and chronic diseases, having closed an oversubscribed pre-seed round in Q3 2025.NasdaqPerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR AtlasPerturbAI, an AI-native therapeutics company, emerged from stealth and released the world's largest in vivo CRISPR atlas containing 8 million brain-wide cells from mouse brains. The atlas, generated in collaboration with NVIDIA, Allen Institute for Brain Science, and 10x Genomics, represents the largest known causal genomics resource generated in living tissue and enables systematic evaluation of gene function within intact biological systems. PerturbAI is utilizing its in vivo CRISPR platform and causal AI models to develop therapeutics for complex metabolic and chronic diseases, having closed an oversubscribed pre-seed round in Q3 2025.PR NewswirePerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR AtlasPerturbAI, an AI-native therapeutics company, emerged from stealth on March 17, 2026, unveiling the world's largest in vivo CRISPR atlas containing 8 million brain-wide cells — the largest known causal genomics resource generated directly in living tissue. The dataset, produced in collaboration with NVIDIA, Allen Institute for Brain Science, and 10x Genomics, maps the effects of thousands of genetic perturbations across hundreds of neuronal cell types in the mouse brain, establishing a new category of biological data. PerturbAI is leveraging its in vivo CRISPR platform and causal AI models to develop therapeutics for complex metabolic and chronic diseases, having closed an oversubscribed pre-seed round in Q3 2025.